/CRBU
CRBU Stock - Caribou Biosciences, Inc.
Healthcare|BiotechnologyNASDAQ
$1.68+3.07%
+$0.05 (+3.07%) • Dec 19
59
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.44
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.16
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+316.7%upside
Target: $7.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CRBU
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.66 – $1.70
TARGET (TP)$7.00
STOP LOSS$1.55
RISK/REWARD1:40.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.60
52W High$3.54
52W Low$0.66
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $9.99M | $34.48M | $13.85M | $9.60M | $12.36M |
| Gross Profit | $6.07M | $30.95M | $10.21M | $8.61M | $-22,064,000 |
| Gross Margin | 60.7% | 89.8% | 73.7% | 89.7% | -178.5% |
| Operating Income | $-166,616,000 | $-116,059,000 | $-106,399,000 | $-66,979,000 | $-36,124,000 |
| Net Income | $-149,105,000 | $-102,070,000 | $-99,421,000 | $-66,923,000 | $-34,308,000 |
| Net Margin | -1491.9% | -296.1% | -717.8% | -697.3% | -277.6% |
| EPS | $-1.65 | $-1.38 | $-1.64 | $-1.11 | $-1.24 |
Company Overview
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
67%
Hold / Neutral
1
33%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
2 Bullish1 Neutral/Bearish
Price Targets
$13
Average Target
↑ 673.8% Upside
Now
$3
Low
$13
Average
$23
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 3rd 2024 | Evercore ISI | Downgrade | In-line | $3← $13 |
| November 8th 2023 | Cantor Fitzgerald | Initiation | Neutral | - |
| October 31st 2023 | Evercore ISI | Initiation | Outperform | $13 |
| July 11th 2023 | Truist | Initiation | Buy | $23 |
Earnings History & Surprises
CRBUBeat Rate
56%
Last 18 quarters
Avg Surprise
-40.4%
EPS vs Estimate
Beats / Misses
10/5
3 met exactly
Latest EPS
$-0.30
Q4 2025
EPS Surprise History
Q1 24
-77.3%
$-0.39vs$-0.22
Q2 24
-17.9%
$-0.46vs$-0.39
Q3 24
+6.7%
$-0.42vs$-0.45
Q4 24
+13.6%
$-0.38vs$-0.44
Q1 25
+2.5%
$-0.39vs$-0.40
Q2 25
0.0%
$-0.43vs$-0.43
Q3 25
+12.5%
$-0.35vs$-0.40
Q4 25
+16.7%
$-0.30vs$-0.36
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 9, 2026 | $-0.33 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.36 | $-0.30 | +16.7% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-0.40 | $-0.35 | +12.5% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.43 | $-0.43 | 0.0% | = MET |
Q1 2025 | Mar 10, 2025 | $-0.40 | $-0.39 | +2.5% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-0.44 | $-0.38 | +13.6% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.45 | $-0.42 | +6.7% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-0.39 | $-0.46 | -17.9% | ✗ MISS |
Q1 2024 | Mar 11, 2024 | $-0.22 | $-0.39 | -77.3% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $-0.38 | $-0.12 | +68.4% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.49 | $-0.48 | +2.0% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.48 | $-0.46 | +4.2% | ✓ BEAT |
Q1 2023 | Mar 9, 2023 | $-0.47 | $-0.44 | +6.4% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-0.48 | $-0.44 | +8.3% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.37 | $-0.46 | -24.3% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-0.35 | $-0.35 | 0.0% | = MET |
Q1 2022 | Mar 21, 2022 | $-0.34 | $-0.34 | 0.0% | = MET |
Q4 2021 | Nov 9, 2021 | $-0.12 | $-0.46 | -280.2% | ✗ MISS |
Q3 2021 | Sep 2, 2021 | $0.42 | $-1.55 | -469.0% | ✗ MISS |
Q3 2021 | Jul 23, 2021 | — | $-0.48 | — | — |
Latest News
Caribou Biosciences Q3 EPS $(0.30) Beats $(0.36) Estimate, Sales $2.198M Miss $2.650M Estimate
➖ NeutralBenzinga•Nov 12, 2025, 09:20 PM
HC Wainwright & Co. Maintains Buy on Caribou Biosciences, Raises Price Target to $9
📈 PositiveBenzinga•Nov 5, 2025, 11:40 AM
CRBU stock has given up its prior gain. Caribou Biosciences shares were trading higher after the company announced its first clinical data from dose escalation in the ongoing CaMMouflage phase 1 trial evaluating CB-011 in relapsed or refractory multiple myeloma.
➖ NeutralBenzinga•Nov 3, 2025, 07:31 PM
Citigroup Maintains Buy on Caribou Biosciences, Raises Price Target to $8
📈 PositiveBenzinga•Nov 3, 2025, 03:17 PM•Also:
Caribou Biosciences shares are trading higher after the company announced its first clinical data from dose escalation in the ongoing CaMMouflage phase 1 trial evaluating CB-011 in relapsed or refractory multiple myeloma.
📈 PositiveBenzinga•Nov 3, 2025, 02:21 PM
Caribou Biosciences Shared Its First Clinical Data From Dose Escalation In The Ongoing CaMMouflage Phase 1 Trial Of CB-011, An Off-The-Shelf Anti-BCMA CAR-T Cell Therapy, In Relapsed Or Refractory Multiple Myeloma; The Company Plans To Share Dose Expansion Data In 2026
📈 PositiveBenzinga•Nov 3, 2025, 12:14 PM
Caribou Biosciences Released Results From Its Ongoing ANTLER Phase 1 Trial Of Vispacabtagene Regedleucel (Formerly Cb-010), An Allogeneic Anti-CD9 CAR-T Cell Therapy, For Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma
➖ NeutralBenzinga•Nov 3, 2025, 12:11 PM
Reported Sunday, Caribou Biosciences Schedules Webcast To Share Key Updates From ANTLER And CaMMouflage Trials And Outline Next Steps For Allogeneic CAR-T Pipeline
➖ NeutralBenzinga•Nov 3, 2025, 07:53 AM
Frequently Asked Questions about CRBU
What is CRBU's current stock price?
Caribou Biosciences, Inc. (CRBU) is currently trading at $1.68 per share. The stock has moved +3.07% today.
What is the analyst price target for CRBU?
The average analyst price target for CRBU is $7.00, based on 1 analyst.
What sector is Caribou Biosciences, Inc. in?
Caribou Biosciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CRBU's market cap?
Caribou Biosciences, Inc. has a market capitalization of $0.16 billion, making it a small-cap company.
Does CRBU pay dividends?
No, Caribou Biosciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAARD
Aardvark Therapeutics, Inc. Common Stock
$13.77
Mkt Cap: $0.3B
ALLO
Allogene Therapeutics, Inc.
$1.42
Mkt Cap: $0.3B
ENTA
Enanta Pharmaceuticals, Inc.
$15.39
Mkt Cap: $0.3B
FHTX
Foghorn Therapeutics Inc.
$5.24
Mkt Cap: $0.3B
HUMA
Humacyte, Inc.
$1.11
Mkt Cap: $0.2B
IVA
Inventiva S.A.
$4.21
Mkt Cap: $0.2B
OBIO
Orchestra BioMed Holdings, Inc.
$4.35
Mkt Cap: $0.2B
PRLD
Prelude Therapeutics Incorporated
$2.14
Mkt Cap: $0.2B
PYXS
Pyxis Oncology, Inc.
$1.27
Mkt Cap: $0.1B
TNYA
Tenaya Therapeutics, Inc.
$0.70
Mkt Cap: $0.1B
Explore stocks similar to CRBU for comparison